|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
12
|
|
pubmed:dateCreated |
2006-11-23
|
|
pubmed:abstractText |
Highly active antiretroviral therapy (HAART) of human immunodeficiency virus-infected patients is associated with adverse effects, such as lipodystrophy and hyperlipidemia. The lipodystrophic syndrome is characterized by a peripheral lipoatrophy and/or fat accumulation in the abdomen and neck. In order to get insights into the physiopathological mechanisms underlying this syndrome, we treated mice with protease inhibitors (PIs) over a long period of time. Although atazanavir-treated mice presented the same circulating triglyceride concentration as control mice, lopinavir-ritonavir-treated mice rapidly became hypertriglyceridemic, with triglyceride levels of 200 mg/dl, whereas control and atazanavir-treated animals had triglyceride levels of 80 mg/dl. These results obtained with mice reproduce the metabolic disorder observed in humans. White adipose tissue (WAT) was analyzed after 8 weeks of treatment. Compared to the control or atazanavir treatment, lopinavir-ritonavir treatment induced a significant 25% weight reduction in the peripheral inguinal WAT depot. By contrast, the profound epididymal WAT depot was not affected. This effect was associated with a 5.5-fold increase in SREBP-1c gene expression only in the inguinal depot. Our results demonstrate that the long-term treatment of mice with PIs constitutes an interesting experimental model with which some aspects of the lipoatrophy induced by HAART in humans may be studied.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/17000748,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17000748-10382692,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17000748-10566684,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17000748-10657860,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17000748-10714567,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17000748-10716495,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17000748-10888979,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17000748-10996400,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17000748-11101056,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17000748-11375339,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17000748-11546771,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17000748-11738387,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17000748-11741158,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17000748-11755538,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17000748-11937183,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17000748-12086554,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17000748-12499212,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17000748-12799555,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17000748-12823953,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17000748-12855691,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17000748-14600514,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17000748-14709251,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17000748-15525648,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17000748-15577646,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17000748-16443758,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17000748-8336713,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17000748-9399962,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17000748-9619798,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17000748-9652687,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17000748-9784493
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
0066-4804
|
|
pubmed:author |
pubmed-author:AouadiMyriamM,
pubmed-author:BinétruyBernardB,
pubmed-author:Cardot-LecciaNathalieN,
pubmed-author:DellamonicaPierreP,
pubmed-author:DurantJacquesJ,
pubmed-author:GarraffoRodolpheR,
pubmed-author:HeripretLaurenceL,
pubmed-author:LavrutThibaudT,
pubmed-author:Le Marchand-BrustelYannickY,
pubmed-author:PerrinChristopheC,
pubmed-author:ProtMatthieuM
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
50
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
3998-4004
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:17000748-Adipose Tissue,
pubmed-meshheading:17000748-Animals,
pubmed-meshheading:17000748-Dose-Response Relationship, Drug,
pubmed-meshheading:17000748-Drug Interactions,
pubmed-meshheading:17000748-HIV Protease Inhibitors,
pubmed-meshheading:17000748-Hypertriglyceridemia,
pubmed-meshheading:17000748-Lopinavir,
pubmed-meshheading:17000748-Male,
pubmed-meshheading:17000748-Mice,
pubmed-meshheading:17000748-Mice, Inbred C57BL,
pubmed-meshheading:17000748-Oligopeptides,
pubmed-meshheading:17000748-Pyridines,
pubmed-meshheading:17000748-Pyrimidinones,
pubmed-meshheading:17000748-RNA, Messenger,
pubmed-meshheading:17000748-Ritonavir,
pubmed-meshheading:17000748-Time Factors,
pubmed-meshheading:17000748-Triglycerides
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Long-term treatment with lopinavir-ritonavir induces a reduction in peripheral adipose depots in mice.
|
|
pubmed:affiliation |
INSERM U568, Nice, France.
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, Non-U.S. Gov't
|
